New Vaccine Has Passed Tests
A new Ebola vaccine developed at the State Scientific center of Virology and Biotechnology Vector has passed the first stage of preclinical trials.
Documents for approval of stage 1 preclinical trials of the vaccine have already been submitted.
Head of Rospotrebnadzor Anna Popova has reported that the new vaccine is quite effective – its effectiveness reaches one hundred per cent after two doses. It may be used both in foci of infection and to protect people at risk.
It is important that the vaccine is stored at plus 4, i.e. at normal vaccine storage conditions. It is different from the vaccines already approved in the Russian Federation as it has another formula. It is a new development based on a new platform.
“We are absolutely confident, says Anna Popova, that the new vaccine will show good results”.